Explore Deeper Protein Insights with Platinum® Pro: From Single-Amino Acid Variants to Quantitative Expression of Protein Barcodes
Presented by Naomi O’Grady – VP Product Marketing, Meredith Carpenter, PhD – Head of Scientific Affairs, and Ilya Chorny, PhD – VP Software and Informatics, Quantum-Si
In this webinar you will learn about the new desktop Next-Generation Protein Sequencer™ from Quantum-Si, Platinum Pro. Servicing protein research applications across proteoform analysis, protein identification, and quantitation of protein expression of barcodes, the Platinum Pro delivers single-amino acid sequencing resolution in an accessible platform with an elegant user experience.
Join us to learn from the leadership team at Quantum-Si as we share more about the Platinum Pro, and present breakthrough data from our recent preprint manuscripts on protein barcoding and proteoform analysis.
Speaker Bio
Naomi O’Grady – VP, Product Marketing
Naomi O’Grady is a global business leader passionate for translating innovation strategy to implementation of winning market initiatives. As Vice President of Product Marketing, Naomileads the product portfolio and market strategy for next-generation protein sequencing at Quantum-Si. With 20+ years progressive experience at leading organizations in diagnostics and life sciences, Naomi has a track record of bringing new to category solutions to market through strategic planning, business development partnerships, global commercial strategy and market development.
Meredith Carpenter, PhD – Head of Scientific Affairs
Meredith L. Carpenter, PhD, is head of scientific affairs at Quantum-Si, where she manages external collaborations and publication strategy. Dr. Carpenter has over 10 years of experience in developing and deploying novel genomics and multi-omics tools in the biotech industry. Prior to Quantum-Si, Dr. Carpenter held roles as director of assay development at Arc Bio and senior director of strategic alliances at Cantata Bio. She earned a BS in Biology from Emory University and a PhD in Molecular and Cell Biology from UC Berkeley, and she performed postdoctoral research in the Department of Genetics at Stanford University.
Ilya Chorny, PhD – VP Software and Informatics
Ilya Chorny, PhD, is a leader in software and data science with extensive expertise in bioinformatics, computational biology, and cloud technologies. As the Vice President of Software & Informatics at Quantum-Si, Ilya spearheads the development of innovative tools for analyzing QSI data, advancing cutting-edge solutions in proteomics and data science.
Before joining Quantum-Si, Chief Technology Officer at PetDx, where he led the software and bioinformatics team to develop the first clinical test for early detection of cancer in dogs.
Ilya has also held leadership positions at WuXi NextCODE, and Illumina where he contributed significantly to product management and strategy for genomic data platforms. At Illumina he led the commercial launch of the BaseSpace Sequence Hub, a SaaS platform for managing and analyzing genomic data.
With a strong foundation in both data science, bioinformatics and software engineering, Ilya has a proven track record of translating complex scientific data into impactful products. He is particularly passionate about advancing the use of data science and cloud technologies to unlock new possibilities in scientific discovery.
Plasma Proteomics 2025: Potential Realized and The Insights Drug Developers Can Expect
Presented by Mo Jain, MD, PhD and Jeramie Watrous, PhD
Plasma proteomics has long held great potential for both biomarker discovery and clinical development, providing a minimally invasive means to measure tissue biology, identify early biomarkers of disease, and monitor disease progression and therapeutic response over time. However, the complexity of the human plasma proteome has precluded broad measure via plasma proteomics and limited its utility for drug development, until now.
This webinar will explore the recent technological developments finally allowing drug developers to extract maximal biological insight from the plasma proteome, with deeper coverage and with greater efficiency for large-scale studies. We will look at methodologies that are overcoming previous trade-offs in measurement speed, sensitivity, and specificity; enrichment techniques enabling detection of biologically/clinically relevant low-abundance proteins in plasma; and why approaches that capture protein isoforms as well as exosomal and membrane-bound proteins have become so critical in 2025.
Importantly, we will review the types of robust analyses that can now be enabled in plasma and share examples of how this data is contributing to the advancement of target identification and precision medicine.
You’ll learn about:
- Prior limitations to harnessing the full discovery potential of the human plasma proteome
- Innovative methods revolutionizing plasma proteomics in 2025
- Actionable insights for drug discovery and development that can be gained through the robust measure and analysis of the breadth of proteins and proteoforms in plasma
Speaker Bio
Mo Jain, MD, PhD
Founder and Chief Scientific Officer, Sapient
Dr. Jain is a physician-scientist with more than 20 years of expertise in physiology, biomedicine, computational biology, and mass spectrometry. Prior to founding Sapient, he formed and was director of Jain Laboratory at the University of California San Diego (UCSD). There he led a multi-disciplinary research team to develop next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems to probe dynamic biomarkers of health, disease, and drug response across population-scale human studies. Dr. Jain founded Sapient in 2021 as a spinout of Jain Laboratory to expand upon the mission of accelerating insight into human biology to advance precision drug development.
Jeramie Watrous, PhD
Co-Founder and Head of Analytical R&D, Sapient
Dr. Watrous is an analytical chemist and engineer with more than a decade of experience using mass spectrometry for biological measures and associated informatics. As a postdoctoral researcher and subsequently an Assistant Professor of Medicine at UCSD, he helped lead the development of fully automated, high throughput mass spectrometry-based workflows for global small molecule biomarker analysis – the next-generation technology that became the basis for Sapient, which he co-founded in 2021. At Sapient, Dr. Watrous oversees the generation, optimization, and standardization of Sapient’s mass spectrometry systems and other innovative instrumentation and lab automation infrastructure.